A large portfolio of previously validated biomarkers are readily available for us on client studies
For confidential advice on your specific project, please feel free to contact us.
Propath offers its clients an extensive portfolio of biomarker methods previously validated by Propath covering a range of indications. Established IHC methods from routine proliferation markers to immuno-oncology markers are available immediately for clinical study samples or for transfer to alternative species.
Rapid tissue screening studies for any of the following validated methods are available at Propath:
PD-1, FoxP3, F4/80, LY-75, CD80
CK19, WT1, CD31, CD71,
Insulin, Collagen IV, GFAP, Iba-1, Podocin